Is ABBV stock a Buy, Sell, or Hold?

Based on our analysis, ABBV is currently a HOLD with moderate confidence. 📊 HOLD: ABBV is fairly valued with market pricing in 3.0% annual growth. Fine to hold or accumulate slowly on dips.

What is the fair value of ABBV stock?

Our analysis estimates the fair value range for ABBV to be between $256.45 and $265.22. The current price is $261.06.

What is the analyst price target for ABBV?

The average Wall Street analyst price target for ABBV is $278.86. This implies a potential upside of 7.3% from current levels.

ABBVIE (ABBV) Stock: Buy, Sell, or Hold?

ABBV - ABBVIE INC.

PHARMACEUTICAL PREPARATIONS

$261.07

1.13 (0.44%) ▲

5d: -1.24%

30d: -0.25%

90d: +2.47%

HOLD

MODERATE Confidence

Protect Your ABBV Gains

Analysis Updated: Oct 2, 2026 12:00 AM ET

Earnings: Oct 30, 2026 27d

Smart Money Distribution

Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →

Signal fired Oct 1, 2026 at $259.93 · last confirmed Oct 1, 2026

Strength: 5.9/10

Get Alerted When ABBV Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
📊 HOLD: ABBV is fairly valued with market pricing in 3.0% annual growth. Fine to hold or accumulate slowly on dips.

See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

Adjust Growth Assumption: 16.1%

0% (Stagnation) 50% (Hyper Growth)

EST. PRICE IN 2031

$384.34

Based on 10.1% avg growth

INTRINSIC VALUE TODAY

$238.65

Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.7x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: ABBV is currently trading at $261.06, which is considered fair relative to its 30-day fair value range of $256.45 to $265.22. The stock's valuation (Forward PE: 16.0) is in line with its historical norms (14.7). At these levels, the market is pricing in 3.0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.

Technical Outlook: Technically, ABBV is in a strong uptrend. The price is currently testing key support at $257.87. A bounce from this level would confirm strength, while a break below could signal further downside.

Market Sentiment: The stock scores a mixed 47/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.

Quick Decision Summary

Current Position FAIR

Historical Trading Range $256.45 - $265.22

Company Quality Score 57/100 (HOLD)

Volume Confirmation HIGH

Confidence Score 68.6%

Protect Your Profits

Holding ABBV? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

NEUTRAL: Price in fair range
NEUTRAL: Mixed technical signals (47/100)
BULLISH: High volume confirmation
NEUTRAL: Near Wall St target ($278.86)
NEUTRAL: Market pricing in 3.0% annual earnings growth - fairly valued
NEUTRAL: Bottoming setup forming (47/100) — watch for confirmation

Trading Range Analysis

30-Day Trading Range $256.45 - $265.22

Current vs Trading Range FAIR

Support & Resistance Levels

Support Level $257.87

Resistance Level $269.39

Current Trend Strong Uptrend

Technical data as of Oct 2, 2026

Fundamental Context

Forward P/E (Next Year Est.) 15.99

Wall Street Target $278.86 (+7.3%)

Revenue Growth (YoY) 10.2%

Earnings Growth (YoY) 290.4%

Profit Margin 9.8%

Valuation Premium vs History +3.0% premium

PE vs Historical 16.0 vs 14.7 FAIR

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): +3.0% (market-implied from PE analysis)

1-Year Target $267.73 (+3%)

2-Year Target $275.76 (+6%)

3-Year Target $284.03 (+9%)

3-Yr Target (if PE normalizes) (PE: 16→15) PE COMPRESSION $261.17 (+1%)

Earnings growth offset by PE compression

3-Year Scenarios Using analyst projected EPS growth

Bull: (PE: 20.4, Growth: 16.1%) $518.71 (+100%)

Base: (SPY PE: 16.0, Growth: 16.1%) $406.50 (+56%)

Bear: (PE: 13.6, Growth: 16.1%) $345.52 (+33%)

📈 Valuation based on Current Earnings

RECOVERY PLAY: Stock looks expensive now (16x PE), but valuation improves significantly next year (16x PE) as earnings recover.

Forward PE: 16.39 | Forward EPS (Implied): $15.86

Bull Case $313.87 (+21%)

Analyst growth 15.0%, PE expands to 17.2

Base Case $259.93 (0%)

Market implied 0.0%, PE stable at 16.4

Bear Case $198.85 (-24%)

Severe decline -15.0%, PE contracts to 14.8

These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.

Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit

bloggers & journalists: you are free to use our charts with attribution.

Last updated: October 02, 2026 1:32 PM ET
Data refreshes hourly during market hours. Next update: 2:32 PM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is ABBV showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check

Insider Activity (6 Months)

Buys

Sells

Net

NEUTRAL

View Insider Activity Scanner

Unlock Insider Activity

See real-time buying/selling by company executives for ABBV.

Create Free Account

Already have an account? Log In

Featured in Portfolios

ABBV is a key holding in these high-performance investment strategies.

Healthcare Giants Sector • +15.9% Return

View All Strategies

Top Rated Drug Manufacturers - General Stocks

Top-rated stocks in Drug Manufacturers - General by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
LLY Eli Lilly and Company	STRONG BUY 31 analysts	$1325	48 HOLD
GILD Gilead Sciences Inc	BUY 30 analysts	$159	46 HOLD
AMGN Amgen Inc	HOLD 32 analysts	$389	55 HOLD
BIIB Biogen Inc	HOLD 37 analysts	$238	48 HOLD
MRK Merck & Company Inc	BUY 26 analysts	$154	55 HOLD

LLY Eli Lilly and Com…

48 HOLD

GILD Gilead Sciences I…

MRK Merck & Company I…

55 HOLD

Advanced ABBV Option Strategies

Professional options setups generated by AI based on today's ABBV price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for ABBV

ABBV Technical Chart ABBV Price Prediction ABBV Earnings Date ABBV Investment Advisor ABBV Fair Price Analyzer ABBV Options Advisor ABBV Options Chain ABBV Options Analysis ABBV Competitors

Compare ABBV with Peers

ABBV vs ABT
Which one to buy?

ABBV vs BMY
Which one to buy?

ABBV vs JNJ
Which one to buy?

ABBV vs GILD
Which one to buy?

ABBV vs MRK
Which one to buy?

Create New Comparison View All Competitors

Tradestie